<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33709219</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>268</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Eye movement alterations in presymptomatic C9orf72 expansion gene carriers.</ArticleTitle><Pagination><StartPage>3390</StartPage><EndPage>3399</EndPage><MedlinePgn>3390-3399</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-021-10510-z</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The clinical manifestation of amyotrophic lateral sclerosis (ALS) is characterized by motor neuron degeneration, whereas frontotemporal dementia (FTD) patients show alterations of behavior and cognition. Both share repeat expansions in C9orf72 as the most prevalent genetic cause. Before disease-defining symptoms onset, structural and functional changes at cortical level may emerge in C9orf72 carriers. Here, we characterized oculomotor parameters and their association to neuropsychological domains in apparently asymptomatic individuals with mutations in ALS/FTD genes.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Forty-eight carriers of ALS genes, without any clinical symptoms underwent video-oculographic examination, including 22 subjects with C9orf72 mutation, 17 with SOD1, and 9 with other ALS associated gene mutations (n&#x2009;=&#x2009;3 KIF5A; n&#x2009;=&#x2009;3 FUS/FUS&#x2009;+&#x2009;TBK1; n&#x2009;=&#x2009;1 NEK1; n&#x2009;=&#x2009;1 SETX; n&#x2009;=&#x2009;1 TDP43). A total of 17 subjects underwent a follow-up measurement. Data were compared to 54 age- and gender-matched healthy controls. Additionally, mutation carriers performed a neuropsychological assessment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In comparison to controls, the presymptomatic subjects performed significantly worse in executive oculomotor tasks such as the ability to perform correct anti-saccades. A gene mutation subgroup analysis showed that dysfunctions in C9orf72 carriers were much more pronounced than in SOD1 carriers. The anti-saccade error rate of ALS mutation carriers was associated with cognitive deficits: this correlation was increased in subjects with C9orf72 mutation, whereas SOD1 carriers showed no associations.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In C9orf72 carriers, executive eye movement dysfunctions, especially the increased anti-saccade error rate, were associated with cognitive impairment and unrelated to time. These oculomotor impairments are in support of developmental deficits in these mutations, especially in prefrontal areas.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Behler</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knehr</LastName><ForeName>Antje</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finsel</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuropsychology, Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunz</LastName><ForeName>Martin S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Hans-Peter</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinkhardt</LastName><ForeName>Elmar H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lul&#xe9;</LastName><ForeName>Doroth&#xe9;e</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neuropsychology, Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kassubek</LastName><ForeName>Jan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7106-9270</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany. jan.kassubek@uni-ulm.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C500506">KIF5A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064251">Multifunctional Enzymes</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C484368">SETX protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.-</RegistryNumber><NameOfSubstance UI="D004265">DNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D020365">RNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.4</RegistryNumber><NameOfSubstance UI="D016547">Kinesins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="Y">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004265" MajorTopicYN="N">DNA Helicases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005133" MajorTopicYN="Y">Eye Movements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016547" MajorTopicYN="N">Kinesins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064251" MajorTopicYN="N">Multifunctional Enzymes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020365" MajorTopicYN="N">RNA Helicases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">Cognition</Keyword><Keyword MajorTopicYN="N">Presymptomatic gene carriers</Keyword><Keyword MajorTopicYN="N">Saccades</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>12</Day><Hour>7</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33709219</ArticleId><ArticleId IdType="pmc">PMC8357645</ArticleId><ArticleId IdType="doi">10.1007/s00415-021-10510-z</ArticleId><ArticleId IdType="pii">10.1007/s00415-021-10510-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benatar M, Wuu J, Andersen PM, et al. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion: neurofilament light in presymptomatic ALS. Ann Neurol. 2018;84:130&#x2013;139. doi: 10.1002/ana.25276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Chipika RH, Siah WF, McKenna MC, et al. The presymptomatic phase of amyotrophic lateral sclerosis: are we merely scratching the surface? J Neurol. 2020 doi: 10.1007/s00415-020-10289-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10289-5</ArticleId><ArticleId IdType="pubmed">33130950</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeldman E, Raaphorst J, Klein Twennaar M, et al. The cognitive profile of ALS: a systematic review and meta-analysis update. J Neurol Neurosurg Psychiatry. 2016;87:611&#x2013;619. doi: 10.1136/jnnp-2015-310734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310734</ArticleId><ArticleId IdType="pubmed">26283685</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, B&#xf6;hm S, M&#xfc;ller H-P, et al. Cognitive phenotypes of sequential staging in amyotrophic lateral sclerosis. Cortex. 2018;101:163&#x2013;171. doi: 10.1016/j.cortex.2018.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cortex.2018.01.004</ArticleId><ArticleId IdType="pubmed">29477906</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasper E, Schuster C, Machts J, et al. Microstructural white matter changes underlying cognitive and behavioural impairment in ALS&#x2013;an in vivo study using DTI. PLoS ONE. 2014;9:e114543. doi: 10.1371/journal.pone.0114543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0114543</ArticleId><ArticleId IdType="pmc">PMC4263750</ArticleId><ArticleId IdType="pubmed">25501028</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; DE, M&#xfc;ller H-P, Finsel J, et al. Deficits in verbal fluency in presymptomatic C9orf72 mutation gene carriers&#x2014;a developmental disorder. J Neurol Neurosurg Psychiatry. 2020 doi: 10.1136/jnnp-2020-323671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323671</ArticleId><ArticleId IdType="pmc">PMC7569387</ArticleId><ArticleId IdType="pubmed">32855285</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-Linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh T-H, Liu H-F, Li Y-W, et al. C9orf72 is essential for neurodevelopment and motility mediated by Cyclin G1. Exp Neurol. 2018;304:114&#x2013;124. doi: 10.1016/j.expneurol.2018.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2018.03.002</ArticleId><ArticleId IdType="pubmed">29522758</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology. 2012;79:1732&#x2013;1739. doi: 10.1212/WNL.0b013e31826e9b1d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31826e9b1d</ArticleId><ArticleId IdType="pmc">PMC3468777</ArticleId><ArticleId IdType="pubmed">23071166</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudfoot M, Menke RAL, Sharma R, et al. Eye-tracking in amyotrophic lateral sclerosis: a longitudinal study of saccadic and cognitive tasks. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17:101&#x2013;111. doi: 10.3109/21678421.2015.1054292.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1054292</ArticleId><ArticleId IdType="pmc">PMC5127416</ArticleId><ArticleId IdType="pubmed">26312652</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaunak S, Orrell RW, O&#x2019;Sullivan E, et al. Oculomotor function in amyotrophic lateral sclerosis: evidence for frontal impairment. Ann Neurol. 1995;38:38&#x2013;44. doi: 10.1002/ana.410380109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410380109</ArticleId><ArticleId IdType="pubmed">7611722</ArticleId></ArticleIdList></Reference><Reference><Citation>Donaghy C, Pinnock R, Abrahams S, et al. Slow saccades in bulbar-onset motor neurone disease. J Neurol. 2010;257:1134&#x2013;1140. doi: 10.1007/s00415-010-5478-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5478-7</ArticleId><ArticleId IdType="pubmed">20146069</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL. Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and alzheimer disease. Arch Neurol. 2012;69:509. doi: 10.1001/archneurol.2011.1021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.1021</ArticleId><ArticleId IdType="pmc">PMC3423186</ArticleId><ArticleId IdType="pubmed">22491196</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorges M, M&#xfc;ller H-P, Lul&#xe9; D, et al. Eye movement deficits are consistent with a staging model of pTDP-43 pathology in amyotrophic lateral sclerosis. PLoS ONE. 2015;10:e0142546. doi: 10.1371/journal.pone.0142546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0142546</ArticleId><ArticleId IdType="pmc">PMC4641606</ArticleId><ArticleId IdType="pubmed">26559944</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondler L, M&#xfc;ller K, Khalaji S, et al. Peripheral monocytes are functionally altered and invade the CNS in ALS patients. Acta Neuropathol. 2016;132:391&#x2013;411. doi: 10.1007/s00401-016-1548-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1548-y</ArticleId><ArticleId IdType="pubmed">26910103</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, Burkhardt C, Abdulla S, et al. The edinburgh cognitive and behavioural amyotrophic lateral sclerosis screen: a cross-sectional comparison of established screening tools in a German-Swiss population. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:16&#x2013;23. doi: 10.3109/21678421.2014.959451.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959451</ArticleId><ArticleId IdType="pubmed">25292386</ArticleId></ArticleIdList></Reference><Reference><Citation>Loose M, Burkhardt C, Aho-&#xd6;zhan H, et al. Age and education-matched cut-off scores for the revised German/Swiss-German version of ECAS. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:374&#x2013;376. doi: 10.3109/21678421.2016.1162814.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1162814</ArticleId><ArticleId IdType="pubmed">27027323</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkhardt EH, Kassubek J, S&#xfc;ssmuth S, et al. Comparison of smooth pursuit eye movement deficits in multiple system atrophy and Parkinson&#x2019;s disease. J Neurol. 2009;256:1438&#x2013;1446. doi: 10.1007/s00415-009-5131-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5131-5</ArticleId><ArticleId IdType="pubmed">19363627</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorges M, M&#xfc;ller H-P, Lul&#xe9; D, et al. Functional connectivity within the default mode network is associated with saccadic accuracy in Parkinson&#x2019;s disease: a resting-state fMRI and videooculographic study. Brain Connectivity. 2013;3:265&#x2013;272. doi: 10.1089/brain.2013.0146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/brain.2013.0146</ArticleId><ArticleId IdType="pubmed">23627641</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker W, Gorges M, Lul&#xe9; D, et al. Saccadic intrusions in amyotrophic lateral sclerosis (ALS) J Eye Mov Res. 2019;12:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7962685</ArticleId><ArticleId IdType="pubmed">33828758</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkhardt EH, Issa H, Gorges M, et al. Do eye movement impairments in patients with small vessel cerebrovascular disease depend on lesion load or on cognitive deficits? A video-oculographic and MRI study. J Neurol. 2014;261:791&#x2013;803. doi: 10.1007/s00415-014-7275-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-014-7275-1</ArticleId><ArticleId IdType="pubmed">24535136</ArticleId></ArticleIdList></Reference><Reference><Citation>Terao Y, Fukuda H, Yugeta A, et al. Initiation and inhibitory control of saccades with the progression of Parkinson&#x2019;s disease&#x2014;changes in three major drives converging on the superior colliculus. Neuropsychologia. 2011;49:1794&#x2013;1806. doi: 10.1016/j.neuropsychologia.2011.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropsychologia.2011.03.002</ArticleId><ArticleId IdType="pubmed">21420990</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkhardt EH, J&#xfc;rgens R, Lul&#xe9; D, et al. Eye movement impairments in Parkinson&#x2019;s disease: possible role of extradopaminergic mechanisms. BMC Neurol. 2012;12:5. doi: 10.1186/1471-2377-12-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-12-5</ArticleId><ArticleId IdType="pmc">PMC3306761</ArticleId><ArticleId IdType="pubmed">22375860</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol. 2013;12:368&#x2013;380. doi: 10.1016/S1474-4422(13)70026-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70026-7</ArticleId><ArticleId IdType="pubmed">23518330</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J, Elamin M, Bede P, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2012;83:102&#x2013;108. doi: 10.1136/jnnp-2011-300188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-300188</ArticleId><ArticleId IdType="pubmed">21836033</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6:994&#x2013;1003. doi: 10.1016/S1474-4422(07)70265-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70265-X</ArticleId><ArticleId IdType="pubmed">17945153</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; DE, Aho-&#xd6;zhan HEA, V&#xe1;zquez C, et al. Story of the ALS-FTD continuum retold: rather two distinct entities. J Neurol Neurosurg Psychiatry. 2019;90:586&#x2013;589. doi: 10.1136/jnnp-2018-318800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318800</ArticleId><ArticleId IdType="pubmed">30257969</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Ziemann U, Eisen A. Amyotrophic lateral sclerosis: origins traced to impaired balance between neural excitation and inhibition in the neonatal period. Muscle Nerve. 2019;60:232&#x2013;235. doi: 10.1002/mus.26617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26617</ArticleId><ArticleId IdType="pubmed">31233613</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz DP, Broughton JR, Goldring JE, Armstrong IT. Age-related performance of human subjects on saccadic eye movement tasks. Exp Brain Res. 1998;121:391&#x2013;400. doi: 10.1007/s002210050473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002210050473</ArticleId><ArticleId IdType="pubmed">9746145</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer B, Weber H. Characteristics of &#x2018;anti&#x2019; saccades in man. Exp Brain Res. 1992 doi: 10.1007/BF00228257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00228257</ArticleId><ArticleId IdType="pubmed">1623983</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Xu J. C9orf72 dipeptide repeats cause selective neurodegeneration and cell-autonomous excitotoxicity in drosophila glutamatergic neurons. J Neurosci. 2018;38:7741&#x2013;7752. doi: 10.1523/JNEUROSCI.0908-18.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0908-18.2018</ArticleId><ArticleId IdType="pmc">PMC6705968</ArticleId><ArticleId IdType="pubmed">30037833</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbutt S, Matlin A, Hellmuth J, et al. Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer&#x2019;s disease. Brain. 2008;131:1268&#x2013;1281. doi: 10.1093/brain/awn047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn047</ArticleId><ArticleId IdType="pmc">PMC2367697</ArticleId><ArticleId IdType="pubmed">18362099</ArticleId></ArticleIdList></Reference><Reference><Citation>Floeter MK, Gendron TF. Biomarkers for amyotrophic lateral sclerosis and frontotemporal dementia associated with hexanucleotide expansion mutations in C9orf72. Front Neurol. 2018;9:1063. doi: 10.3389/fneur.2018.01063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01063</ArticleId><ArticleId IdType="pmc">PMC6289985</ArticleId><ArticleId IdType="pubmed">30568632</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Siah WF, McKenna MC, Li Hi Shing S. Consideration of C9orf72 -associated ALS-FTD as a neurodevel&#xad;opmental disorder: insights from neuroimaging. J Neurol Neurosurg Psychiatry. 2020;91:1138&#x2013;1138. doi: 10.1136/jnnp-2020-324416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-324416</ArticleId><ArticleId IdType="pubmed">32855286</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xfa;lio F, Caetano G, Janu&#xe1;rio C, Castelo-Branco M. The effect of impulsivity and inhibitory control deficits in the saccadic behavior of premanifest Huntington&#x2019;s disease individuals. Orphanet J Rare Dis. 2019;14:246. doi: 10.1186/s13023-019-1218-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-019-1218-y</ArticleId><ArticleId IdType="pmc">PMC6839196</ArticleId><ArticleId IdType="pubmed">31703597</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira CM, Leotti VB, Bolzan G, et al. Pre-ataxic changes of clinical scales and eye movement in machado-joseph disease: BIGPRO study. Mov Disord Epub mds. 2021 doi: 10.1002/mds.28466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28466</ArticleId><ArticleId IdType="pubmed">33438269</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>